Healthcare
Executive compensation benchmarks for 9 public companies in the biological products, (no diagnostic substances) industry.
$10.4M
9
$33.2M
Median
$10,442,485
Average
$13,141,577
25th Percentile
$7,807,786
75th Percentile
$14,672,390
Minimum
$4,069,913
Maximum
$33,239,183
Companies
9
Click any company to see full compensation breakdown
The median biological products, (no diagnostic substances) CEO compensation is $10,442,485, based on 9 public companies. The average is $13,141,577. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Michael M. Morrissey of EXELIXIS, INC. is the highest paid biological products, (no diagnostic substances) CEO, with total compensation of $33,239,183 in FY2025.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: October 14, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| EXELIXIS, INC. EXEL | Michael M. Morrissey | $33.2M |
| Vir Biotechnology, Inc. VIR | George Scangos | $20.7M |
| Revolution Medicines, Inc. RVMD | Mark A. Goldsmith | $14.7M |
| Vericel Corp VCEL | Dominick Colangelo | $11.2M |
| Krystal Biotech, Inc. KRYS | Krish S. Krishnan | $10.4M |
| ADMA BIOLOGICS, INC. ADMA | Adam S. Grossman | $10.2M |
| ARGENX SE ARGX | Tim Van Hauwermeiren | $7.8M |
| Cidara Therapeutics, Inc. CDTX | Jeffrey Stein | $6.0M |
| BIOGEN INC. BIIB | Christopher A. Viehbacher | $4.1M |